CA2668859A1 - Pyrimidine derivatives as posh and posh-ap inhibitors - Google Patents

Pyrimidine derivatives as posh and posh-ap inhibitors Download PDF

Info

Publication number
CA2668859A1
CA2668859A1 CA002668859A CA2668859A CA2668859A1 CA 2668859 A1 CA2668859 A1 CA 2668859A1 CA 002668859 A CA002668859 A CA 002668859A CA 2668859 A CA2668859 A CA 2668859A CA 2668859 A1 CA2668859 A1 CA 2668859A1
Authority
CA
Canada
Prior art keywords
compound
posh
polypeptide
virus
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002668859A
Other languages
English (en)
French (fr)
Inventor
Philippe Nakache
Itzchak Angel
Nurit Livnah
Maxim Borovitov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteologics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2668859A1 publication Critical patent/CA2668859A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002668859A 2006-11-07 2007-11-07 Pyrimidine derivatives as posh and posh-ap inhibitors Abandoned CA2668859A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85737806P 2006-11-07 2006-11-07
US60/857,378 2006-11-07
US95983107P 2007-07-17 2007-07-17
US60/959,831 2007-07-17
PCT/IL2007/001356 WO2008056356A2 (en) 2006-11-07 2007-11-07 Pyrimidine derivatives as posh and posh-ap inhibitors

Publications (1)

Publication Number Publication Date
CA2668859A1 true CA2668859A1 (en) 2008-05-15

Family

ID=39364907

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002668859A Abandoned CA2668859A1 (en) 2006-11-07 2007-11-07 Pyrimidine derivatives as posh and posh-ap inhibitors

Country Status (6)

Country Link
US (2) US8283355B2 (enExample)
EP (1) EP2083826A4 (enExample)
JP (1) JP2010509205A (enExample)
AU (1) AU2007318922C1 (enExample)
CA (1) CA2668859A1 (enExample)
WO (1) WO2008056356A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120116425A (ko) * 2009-11-30 2012-10-22 프로테오로직스 엘티디 작은 피리미딘 유도체 및 이의 사용 방법
WO2013088445A1 (en) * 2011-12-13 2013-06-20 Proteologics Ltd Pyrimidine derivatives for treatment of inflammatory diseases
GB201415688D0 (en) * 2014-09-04 2014-10-22 Univ Edinburgh Method and Systems
SG10201913958QA (en) * 2015-07-15 2020-03-30 Agency Science Tech & Res Modulation of hepatitis b virus replication
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
MA53086B1 (fr) * 2018-07-05 2024-07-31 Bayer Aktiengesellschaft Thiophènecarboxamides substitués et analogues comme agents antibactériens
US20220193041A1 (en) * 2019-04-02 2022-06-23 Yonsei University, University - Industry Foundation (UIF) Novel compound and method for preventing or treating of respiratory diseases comprising the same as an active ingredient
CN110760597B (zh) * 2019-11-22 2022-08-23 西北农林科技大学 一种检测黄牛ncstn基因拷贝数变异的方法及其应用
TW202527955A (zh) * 2023-11-27 2025-07-16 美商尼坎醫療公司 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶2和週期蛋白依賴性激酶4的含有2,5-取代的嘧啶衍生物的雙功能化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734081A (en) 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
JP2004515235A (ja) 2000-12-08 2004-05-27 ノボ ノルディスク アクティーゼルスカブ Tffペプチド
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
CA2456754A1 (en) * 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
AU2004263179B8 (en) * 2003-08-08 2011-07-14 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US20050214751A1 (en) 2004-03-02 2005-09-29 Proteologics, Inc. Inhibition of viral maturation, methods and compositions related thereto
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto

Also Published As

Publication number Publication date
EP2083826A4 (en) 2010-09-22
AU2007318922B2 (en) 2013-01-10
US8283355B2 (en) 2012-10-09
AU2007318922C1 (en) 2013-09-12
WO2008056356A3 (en) 2009-09-03
WO2008056356A2 (en) 2008-05-15
JP2010509205A (ja) 2010-03-25
EP2083826A2 (en) 2009-08-05
AU2007318922A1 (en) 2008-05-15
US20130131094A1 (en) 2013-05-23
US20100179178A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
US20130131094A1 (en) Pyrimidine derivatives as posh and posh-ap inhibitors
US9765019B2 (en) Small-molecule-targeted protein degradation
US7659277B2 (en) Ubiquitin ligase inhibitors and methods related thereto
Agola et al. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition
Wang et al. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4, 7-dimethoxy-1 H-pyrrolo [2, 3-c] pyridin-3-yl) ethane-1, 2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects
AU2004268647B2 (en) Modulation of beta-catenin/TCF activated transcription
Donkor An update on the therapeutic potential of calpain inhibitors: a patent review
CN107531683A (zh) Usp7抑制剂化合物及使用方法
Wang et al. A survey of core replacements in indole-based HIV-1 attachment inhibitors
Blaquiere et al. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases
US20120015967A1 (en) Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors
JP2023541040A (ja) 筋ジストロフィーを処置するための組成物及び方法
US20050214751A1 (en) Inhibition of viral maturation, methods and compositions related thereto
EP1646644A2 (en) Posh interacting proteins and related methods
AU2005279845A1 (en) Inhibition of viruses using RNase H inhibitors
Bao et al. Betulinic acid acetate, an antiproliferative natural product, suppresses client proteins of heat shock protein pathways through a CDC37-binding mechanism
US20060286630A1 (en) Posh interacting proteins and related methods
US20190352297A1 (en) Selective aurora a kinase inhibitors
Shouksmith Design and synthesis of small-molecule inhibitors targeting the SCFSKP2 E3 ligase and the MDMX-p53 interaction for cancer therapy
하재영 Development and applications of thermal stability shift-based methodology for label-free target protein identification
WO2021183942A1 (en) Inhibitors of hsp70 proteins
Metwaly Drug Design and Development of Antivirals and Fluorescent Anion Transporters
WO2004098492A2 (en) Trans-golgi network-associated processes, methods and compositions related thereto
Tjin Mechanism-and Structure-Based Development of Small Molecule Inhibitors Against Therapeutically Important Enzymes
WO2004073609A2 (en) Posh associated kinases and related methods

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150223